Michael Laska, PhD

Michael Laska is Senior Vice President, Technical Development at Mirai Bio. He has a breadth of knowledge and experience in process development, CMC, and manufacturing of novel vaccines and therapeutics.

Prior to Mirai, Michael held leadership roles at Sana Biotechnology as Head of Manufacturing and Site Operations and Vice President of Technical Research, where he was responsible for early CMC development of a novel targeted gene therapy platform originated at Flagship Pioneering. Michael also served as Vice President, CMC Development and Manufacturing for gene editing programs at Casebia Therapeutics. Previously, Michael was Head of Process Development at Moderna Therapeutics, leading process development, scale-up, and early manufacturing of mRNA technology for Moderna’s first wave of clinical programs and pandemic readiness.  He also held various technical and leadership roles at Merck & Co in bioprocess research and development for vaccines and biologics.

Michael has a PhD in Chemical Engineering from MIT.